Multi-center phase 1B trial of ACY-1215 (Ricolinostat) combined with nab-paclitaxel in unresectable or metastatic breast cancer
A study for patients with metastatic breast cancer using study drug Ricolinostat in combination with nab-paclitaxel
Sponsor: Acetylon
Enrolling: Male and Female Patients
IRB Number: AAAQ3709
U.S. Govt. ID: NCT02632071
Contact: Research Nurse Navigator: 212-342-5162 / cancerclinicaltrials@cumc.columbia.edu
Additional Study Information: The purpose of this study is to determine the MTD of Ricolinostat (ACY-1215) in combination with weekly abraxane as well as evaluate the safety and tolerablility of Ricolinostat (ACY-1215) in combination with weekly abraxane.
This study is closed
Investigator
Kevin Kalinsky, MD, MS
Do You Qualify?
Have you been diagnosed with breast cancer? Yes No
Submit
Cancel
You may be eligible for this study

Place Holder



Cancel
For more information, please contact:
Research Nurse Navigator
cancerclinicaltrials@cumc.columbia.edu
212-342-5162
This website uses cookies as well as similar tools and technologies to understand visitors’ experiences. By continuing to use this website, you consent to Columbia University’s usage of cookies and similar technologies, in accordance with the Columbia University Website Cookie Notice.
I AGREE